These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31588878)

  • 1. CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
    Lauschke VM; Nordling Å; Zhou Y; Fontalva S; Barragan I; Ingelman-Sundberg M
    Pharmacogenomics; 2019 Oct; 20(15):1085-1092. PubMed ID: 31588878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
    Song HY; Xia JS; Chen YG; Chen L
    Hum Exp Toxicol; 2022; 41():9603271221080236. PubMed ID: 35099304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
    Song HY; Xia JS; Chen YG; Chen L
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S646-S653. PubMed ID: 34784831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
    Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
    Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.
    Yang C; Guo L; Du J; Zhang Q; Zhang L
    Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
    García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
    Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients.
    Guo XG; Wang ZH; Dong W; He XD; Liu FC; Liu H
    Biomed Environ Sci; 2018 Aug; 31(8):586-595. PubMed ID: 30231963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
    Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
    Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.
    Mirghani RA; Sayi J; Aklillu E; Allqvist A; Jande M; Wennerholm A; Eriksen J; Herben VM; Jones BC; Gustafsson LL; Bertilsson L
    Pharmacogenet Genomics; 2006 Sep; 16(9):637-45. PubMed ID: 16906018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.
    Kitzmiller JP; Luzum JA; Baldassarre D; Krauss RM; Medina MW
    Pharmacogenet Genomics; 2014 Oct; 24(10):486-91. PubMed ID: 25051018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP3A5 genotype-phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele.
    Bolbrinker J; Seeberg S; Schostak M; Kempkensteffen C; Baelde H; de Heer E; Kreutz R
    Drug Metab Dispos; 2012 Apr; 40(4):639-41. PubMed ID: 22214815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
    Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
    Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
    Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
    Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
    Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
    Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case-control study on the association of hepatocellular carcinoma with genetic polymorphisms of CYP3A5 in a highly aflatoxin B1 contaminated Guangxi area].
    Lu HX; Feng ZB; Feng XL
    Zhonghua Gan Zang Bing Za Zhi; 2007 Sep; 15(9):705-6. PubMed ID: 17903382
    [No Abstract]   [Full Text] [Related]  

  • 19. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies.
    Sun Z; Zhao Z; Li G; Dong S; Huang Z; Ye L; Liang H; Qu J; Ai X; Zhang W; Chen X
    Tumori; 2010; 96(1):90-6. PubMed ID: 20437864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.